A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors Merck & Co
- 02 Sep 2015 According to Merck & Co. media release, supplemental NDA for aprepitant (EMEND) in combination with other antiemetics has been approved by the US FDA for use in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg for the prevention of chemotherapy induced nausea and vomiting based partly on data from this trial.
- 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 30 Apr 2012 New trial record